logo BDSP

Base documentaire


  1. Fulltext. The effects of planned duration of residential drug abuse treatment on recovery and HIV risk behavior.

    Article - En anglais

    Fulltext.

    Objective

    This study assessed the effects of planned duration of residential drug abuse treatment on recovery from drug use and on human immunodeficiency virus (HIV) risk behaviors.

    Methods

    Two concurrent randomized controlled trials of programs differing in planned duration were conducted : 6-month vs 12-month versions of a traditional therapeutic community program, and 3-month vs 6-month versions of a modified therapeutic community incorporating a relapse prevention and health education program.

    Outcomes, measured at least 16.5 months after admission, included time from admission to first drug use ; severity of drug, alcohol, legal, and employment problems ; and risky drug injection and sexual behaviors.

    Results

    Among 539 clients (86% of those enrolled), there were no significant effects of planned duration of treatment upon Addiction Severity Index scores or HIV risk behavior.

    In the relapse prevention program, clients randomized to the 6-month program had a longer time to first drug use than those in the 3-month program (hazard ratio=0.74 ; 95% confidence interval=0.58,0.93).

    Employment problems at follow-up were significantly less severe among clients treated in the therapeutic community than among those in the relapse prevention program.

    Conclusions

    No overall benefit of extending treatment beyond 6 months was found.

    Mots-clés Pascal : Traitement communautaire, Toxicomanie, Education santé, Prévention, Etude comparative, Homme, Durée, Pronostic, Prise risque, Virus immunodéficience humaine, Lentivirinae, Retroviridae, Virus, Programme thérapeutique, Sevrage toxique, Santé mentale, Etats Unis, Amérique du Nord, Amérique

    Mots-clés Pascal anglais : Community treatment, Drug addiction, Health education, Prevention, Comparative study, Human, Duration, Prognosis, Risk taking, Human immunodeficiency virus, Lentivirinae, Retroviridae, Virus, Therapeutic schedule, Poison withdrawal, Mental health, United States, North America, America

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 97-0551682

    Code Inist : 002B18I15. Création : 24/03/1998.